<DOC>
	<DOCNO>NCT00278915</DOCNO>
	<brief_summary>The purpose study evaluate safety , effectiveness pharmacokinetics study drug call Faslodex ( fulvestrant ) treatment progressive precocious puberty ( early puberty ) girls McCune-Albright syndrome ( MAS ) .</brief_summary>
	<brief_title>Faslodex McCune Albright Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Fibrous Dysplasia , Polyostotic</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Females less equal 10 year age ( prior 11th birthday ) Diagnosis McCuneAlbright syndrome ( MAS ) Progressive precocious puberty ( PPP ) associate MAS Received prior treatment PPP associate MAS fulvestrant Abnormal platelet count liver function test Bleeding disorder Long term anticoagulation therapy Known hypersensitivity component study drug</criteria>
	<gender>Female</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Progressive Precocious Puberty</keyword>
	<keyword>PPP</keyword>
	<keyword>McCune-Albright Syndrome</keyword>
	<keyword>MAS</keyword>
</DOC>